Literature DB >> 28880983

Chimeric Antigen Receptor (CAR) T-Cell Therapy.

John M Pagel, Howard Jack West.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28880983     DOI： 10.1001/jamaoncol.2017.2989

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  5 in total

1.  CARs on a highway with roadblocks.

Authors:  Lorenzo Galluzzi; Peter Martin
Journal:  Oncoimmunology       Date:  2017-10-11       Impact factor: 8.110

Review 2.  Immunoregulatory Potential of Exosomes Derived from Cancer Stem Cells.

Authors:  Shannon M Clayton; Joehleen A Archard; Joseph Wagner; D Gregory Farwell; Arnaud F Bewley; Angela Beliveau; Andrew Birkeland; Shyam Rao; Marianne Abouyared; Peter C Belafsky; Johnathon D Anderson
Journal:  Stem Cells Dev       Date:  2020-01-30       Impact factor: 3.272

3.  In Vivo Cellular Expansion of Lisocabtagene Maraleucel and Association With Efficacy and Safety in Relapsed/Refractory Large B-Cell Lymphoma.

Authors:  Ken Ogasawara; James Lymp; Timothy Mack; Justine Dell'Aringa; Chang-Pin Huang; Jeff Smith; Leanne Peiser; Ana Kostic
Journal:  Clin Pharmacol Ther       Date:  2022-03-20       Impact factor: 6.903

4.  Recombination of a dual-CAR-modified T lymphocyte to accurately eliminate pancreatic malignancy.

Authors:  Erhao Zhang; Peiwei Yang; Jieyi Gu; Heming Wu; Xiaowei Chi; Chen Liu; Ying Wang; Jianpeng Xue; Weiyan Qi; Qingbo Sun; Shengnan Zhang; Jialiang Hu; Hanmei Xu
Journal:  J Hematol Oncol       Date:  2018-08-13       Impact factor: 17.388

Review 5.  Development of oncolytic virotherapy: from genetic modification to combination therapy.

Authors:  Qiaoshuai Lan; Shuai Xia; Qian Wang; Wei Xu; Haiyan Huang; Shibo Jiang; Lu Lu
Journal:  Front Med       Date:  2020-03-07       Impact factor: 4.592
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.